Cervical Disc Arthroplasty Compared with Arthrodesis for the Treatment of Myelopathy

Buchowski, Jacob M.; Anderson, Paul A.; Sekhon, Lali; Riew, K. Daniel
October 2009
Journal of Bone & Joint Surgery, American Volume;Oct2009 Supplement 2, Vol. 91-A Issue 2, p223
Academic Journal
BACKGROUND: Although there have been case reports describing the use of cervical disc arthroplasty for the treatment of myelopathy, there is a concern that motion preservation may maintain microtrauma to the spinal cord, negatively affecting the clinical results. As we are not aware of any studies on the use of arthroplasty in this scenario, we performed a cross-sectional analysis of two large, prospective, randomized multicenter trials to evaluate the efficacy of cervical disc arthroplasty for the treatment of myelopathy. METHODS: The patients in the current study were a cohort of patients who were enrolled in the United States Food and Drug Administration Investigational Device Exemption studies of the Prestige ST and Bryan disc replacements (Medtronic, Memphis, Tennessee). The inclusion criteria were myelopathy and spondylosis or disc herniation at a single level from C3 to C7. Clinical outcome measures were collected preoperatively and at six weeks, three months, six months, twelve months, and twenty-four months postoperatively. RESULTS: A total of 199 patients were included in the present study; 106 patients (53%) underwent arthroplasty, whereas ninety-three (47%) underwent arthrodesis. The Neck Disability Index, Short Form-36 scores, and specific arm and neck pain scores improved significantly from baseline at all time points. Patients in all four groups had improvement in the postoperative neurological status and gait function; at twenty-four months after surgery, 90% (95% confidence interval, 77.8% to 96.6%) of the patients in the arthroplasty group and 81% (95% confidence interval, 64.9% to 92.0%) of those in the arthrodesis group had improvement in or maintenance of the neurological status in the Prestige ST trial and 90% (95% confidence interval, 75.8% to 97.1%) of the patients in the arthroplasty group and 77% (95% confidence interval, 57.7% to 90.1%) of those in the arthrodesis group had improvement in or maintenance of the neurological status in the Bryan trial. CONCLUSIONS: We found that patients in both the arthroplasty and arthrodesis groups had improvement following surgery; furthermore, improvement was similar between the groups, with no worsening of myelopathy in the arthroplasty group. While the findings at two years postoperatively suggest that arthroplasty is equivalent to arthrodesis for the treatment of cervical myelopathy for a single-level abnormality localized to the disc space, the present study did not evaluate the treatment of retrovertebral compression as occurs in association with ossification of the posterior longitudinal ligament, and we cannot comment on the treatment of this condition. LEVEL OF EVIDENCE: Therapeutic Level II. See Instructions to Authors for a complete description of levels of evidence.


Related Articles

  • The Mobi-C cervical disc for one-level and two-level cervical disc replacement: a review of the literature. Alvin, Matthew D.; Mroz, Thomas E. // Medical Devices: Evidence & Research;2014, Vol. 7, p397 

    Background: Cervical disc arthroplasty (CDA) is a novel motion-preserving procedure that is an alternative to fusion. The Mobi-C disc prosthesis, one of many Food and Drug Administration (FDA)-approved devices for CDA, is the only FDA-approved prosthesis for two-level CDA. Hence, it may allow...

  • Minimally Invasive Hip Resurfacing Compared to Minimally Invasive Total Hip Arthroplasty. Swank, Michael L.; Alkire, Martha R. // Bulletin of the NYU Hospital for Joint Diseases;2009, Vol. 67 Issue 2, p113 

    Background: Since its March 2006 FDA approval in the United States, Birmingham hip resurfacing (BHR) has been a popular alternative to hip arthroplasty, for the younger patient population. Data to date has shown a trend toward low incidence of dislocation and good survivorship. Methods: 128...

  • What's New in Spine Surgery. Bridwell, Keith H.; Anderson, Paul A.; Boden, Scott D.; Vaccaro, Alexander R.; Wang, Jeffrey C. // Journal of Bone & Joint Surgery, American Volume;8/17/2011, Vol. 93-A Issue 16, p1560 

    The article discusses the recent developments in cervical spine treatment as of 2011. It mentions a study of cervical myelopathy which showed a significant result following the determination of differences of anterior and posterior cervical spine surgery. It cites disc arthroplasty which...

  • The mid-term outcome of total ankle arthroplasty and ankle fusion in rheumatoid arthritis: a systematic review. van Heiningen, Jacqueline; Vliet Vlieland, Thea P. M.; van der Heide, Huub J. L. // BMC Musculoskeletal Disorders;2013, Vol. 14 Issue 1, p1 

    Background While arthrodesis is the standard treatment of a severely arthritic ankle joint, total ankle arthroplasty has become a popular alternative. This review provides clinical outcomes and complications of both interventions in patients with rheumatoid arthritis. Methods Studies were...

  • Arthroplasty versus arthrodesis for end-stage ankle arthritis: decision analysis using Markov model. Kwon, Dae; Chung, Chin; Park, Moon; Sung, Ki; Kim, Tae; Lee, Kyoung // International Orthopaedics;Nov2011, Vol. 35 Issue 11, p1647 

    Background: Total ankle arthroplasty and arthrodesis are the two mainstreams of treatment for end-stage ankle arthritis. This study was performed to determine which is a better choice for ankle arthritis, using a decision analysis and Markov model to reflect the repetitive nature of revision...

  • Need for standardization in assessing impact of antibiotic shortages on patient outcomes. Mclaughlin, Milena M.; Pentoney, Zachary; Scheetz, Marc H. // American Journal of Health-System Pharmacy;12/15/2012, Vol. 69 Issue 24, p2129 

    A letter to the editor is presented in response to the article "Food and Drug Administration Safety and Innovation Act" by the U.S. Food and Drug Administration which was issued by September 13, 2012.

  • Repligen Receives U.S. Fast Track Designation and European Orphan Medicinal Product Recommendation for RG3039 for Spinal Muscular Atrophy.  // Biomedical Market Newsletter;6/30/2011, p290 

    The article reports on the fast track designation granted to Waltham, Massachusetts-based Repligen Corp.'s RG3039 orphan medicinal product for Spinal Muscular Atrophy (SMA) by the U.S. Food and Drug Administration (FDA). It states that Repligen's RG3039 has received a recommendation from the...

  • Ionis Pharma Eyes Sustainable Profitability After FDA Approval. KREY, MICHAEL // Investors Business Daily;12/27/2016, p1 

    The article reports that Ionis Pharmaceuticals Inc.'s (IONS) spinal muscular atrophy treatment has been approved by the U.S. Food and Drug Administration (FDA). It is noted that hitting a nearly one-year high, Ionis stock rose 3.2% to 55.12 in the stock market. According to Needham analyst Chad...

  • Difference in chronological changes of outcome measures between untreated and placebo-treated patients of spinal and bulbar muscular atrophy. Hashizume, Atsushi; Katsuno, Masahisa; Banno, Haruhiko; Suzuki, Keisuke; Suga, Noriaki; Tanaka, Fumiaki; Sobue, Gen // Journal of Neurology;Apr2012, Vol. 259 Issue 4, p712 

    Spinal and bulbar muscular atrophy (SBMA) is an adult-onset, X-linked motor neuron disease characterized by muscle atrophy, weakness, and bulbar involvement. The aim of this study was to analyze the differential change of various outcome measures by comparing the progression of motor impairment...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics